Retrospective epidemiological study on the durability of the treatment of HIV infection or AIDS in Spain;Estudio epidemiológico retrospectivo sobre la duración del tratamiento de la infección por el virus de la inmunodeficiencia humana en España

Medicina Clinica

Volumn 119, Issue 19, 2002, Pages 721-724

  Arribas Lopez, José Ramón ^a   Sanz Baena, Susana ^a   Hernández Albujar, Susana ^a   Lorenzo Hernández, Alicia ^a   Montes Ramírez, M Luisa ^a   Palacios Muñoz, Rosario ^b   Márquez Solero, Manuel ^b   Santos González, Jesús ^b   Ocampo Hermida, Antonio ^c   Miralles Álvarez, Celia ^c   López Aldeguer, José ^d   Salavert Lletí, Miguel ^d   Tordera Higón, Pablo ^d   Santamaría Jáuregui, Juan Miguel ^e   Teira Cobo, Ramón M ^e   Moreno Guillén, Santiago ^f   Moreno Zamora, Ana ^f   Gatell Artigas, José M ^g   Mallotas Masferrer, José ^g   Callau Cabrera, Pilar ^g   Torralba González de Suso, Miguel ^h   Costa Cerdá, Asunción ^h   Cepeda González, Concepción ^h   Pulido Ortega, Federico ^h   Condes Moreno, Emilia ⁱ   Barros Aguado, Carlos ⁱ   del Llano Señarís, Juan ^j   Coduras, Alicia ^j   Oliva, Juan ^j   Burgos Ramírez, Ángel ^k   González Lahoz, Juan ^a   Díaz, Beatriz ^a   more..

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL XERAL CÍES   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL DE BASURTO   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL DE MÓSTOLES   (Spain)

^j Fundacion Gaspar Casal   (Spain)

^k ABBOTT LABORATORIES   (Spain)

more..

Author keywords

Adverse events; AIDS; Durability; HIV; Immunological failure; Tolerance; Treatment; Virological failure

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD DISEASE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL DISEASE; HOSPITAL CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIVER DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROPATHY; PRESCRIPTION; RETROSPECTIVE STUDY; SKIN DISEASE; SPAIN; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT WITHDRAWAL;

EID: 12244295438     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(02)73556-2     Document Type: Article

References (27)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Mocroft A, Vella S, Benfield TL, Chisie A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-30.
3. Egger M, Hirschel B, Francioli P, Sucre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997;315:1194-9.
4. Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. J Am Med Assoc 1998;280:1497-503.
5. Hogg R, Heath K, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV infected individuals following initiation of antiretroviral therapy. J Am Med Assoc 1998;279:450-4.
6. Fätkenheuer G, Thisen A, Rockstroh J, Grabow T, Wicke C, Becker K, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11:F113-6.
7. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
8. Paterson D, Swindells S, Mohr J, Brester M, Vergis E, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
9. Haubrich RN, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999;13:1099-107.
10. Riera M, De la Fuente L, Castanyer B, Puigventos F, Villalonga C, Ribas MA, et al. Adherencia a los fármacos antirretrovirales medida por la concentración de fármacos y el recuento de comprimidos. Variables relacionadas con una mala adherencia. Med Clin (Barc) 2002; 119: 286-92.
11. Rubio R, Berenguer J, Miro JM, Antela A, Iribarren A, González J, et al. Recomendaciones de GESIDA/Plan Nacional sobre el sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de ]a inmunodeficiencia humana en el año 2002. Enf Infec Microbiol Clin 2002;20:244-303.
12. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15:185-94.
13. D'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14:499-507.
14. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-53.
15. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998;351:723-4.
16. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
17. Knobel H, Codina C, Miró JM, Carmona A, García B, Antela A, et al. Recomenclaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratarniento antirretroviral. Enferm Infecc Microbiol Clin 2000;18:27-39.
18. Knobel H, Carmona A, Grau S, Pedro-Botet J, Díez A. Adherence and effectiveness of highly active antiretroviral therapy. Arch Intern Mad 1998; 158:1953.
19. Moltó J, Gutiérrez F, Mora A, Masiá MM, Escolano C, González E, et al. Factores asociados a la resistencia a los inhibidores de la proteasa del virus de la inmunodeficiencia humana. Med Clin (Barc) 2002; 118:721-4.
20. Bonfanti P, Ricci E, Landonio S, Valsecchi L, Timillero L, Faggion I, et al. Predictors of protease inhibitor-associated adverse events. Biomed Pharmacother 2001;55:321-3.
21. Swiss HIV Cohort Study. Prevalence of adverse events associated with potent antiretroviral treatment. Lancet 2001;358:1322-7.
22. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15: 231-9.
23. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30 (Suppl 2):171-6.
24. Tuldrá A, Fumaz R, Ferrer MJ, Bayers R, Arno A, Balagué M, et al. Prospective randomised two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;25:221-8.
25. Knobel H, Rubio R, Miró JM, Gatell JM, Del Campo A. Adherence to antiretroviral therapy: the patient's perspective, 7th European Conference on Clinical Aspects and treatment of HIV-infection. Lisboa, 1999.
26. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001 3:865-72.
27. Abellán J, Garrote M, Pulido F, Rubio R, Costa JR. Evaluation of adherence to a triple antiretroviral therapy in HIV-positive patients. Eur J Intern Med 1999;10:202-5.